Trial Profile
A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Dalcetrapib (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Myocardial infarction; Stroke
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms Dal-GenE
- Sponsors DalCor Pharmaceuticals
- 21 Jul 2022 According to a DalCor Pharmaceuticals media release, results from this trial were published in European Heart Journal.
- 21 Jul 2022 Results published in the DalCor Pharmaceuticals Media Release.
- 21 Jul 2022 Primary endpoint (Composite of Major Cardiovascular Adverse Events (MACE), death, MI and stroke in ITT population) has not been met, according to a DalCor Pharmaceuticals media release.